Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: An immunohistochemical study of 1078 cases with diagnostic and therapeutic implications

American Journal of Surgical Pathology

Volumn 37, Issue 1, 2013, Pages 114-119

  Lasota, Jerzy ^a   Wang, Zengfeng ^a   Kim, Su Young ^a   Helman, Lee ^a   Miettinen, Markku ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

gastrointestinal stromal tumor; GIST; IGF1R; immunohistochemistry; insulin like growth factor 1 receptor; pediatric GIST; succinate dehydrogenase

Indexed keywords

SOMATOMEDIN C RECEPTOR; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; DIFFERENTIAL DIAGNOSIS; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE TUMOR; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; SARCOMA;

ADOLESCENT; ADULT; DIAGNOSIS, DIFFERENTIAL; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR, IGF TYPE 1; SARCOMA; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84871618647     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182613c86     Document Type: Article

References (30)

1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit gene in gastrointestinal stromal tumors. Science. 1998;279: 577-580.
2. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299: 708-710.
3. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histo-pathology. 2008;53:245-266.
4. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104:865-873.
5. Gill AJ, Chou A, Vilain R, et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol. 2010;34:805-814.
6. Gaal J, Stratakis CA, Carney JA, et al. SDHB immunohistochem-istry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol. 2011;24:147-151.
7. Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA. 2011;108:314-318.
8. Miettinen M, Wang ZF, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohisto-chemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011;35:1712-1721.
9. Pasini B, McWhinney SR, Bei T, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16:79-88.
10. Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours, and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Int Med. 2009;266:43-52.
11. Carney JA. Carney triad: a syndrome featuring paraganglionic, adrenocortical, and possibly other endocrine tumors. J Clin Endocr Metab. 2009;94:3656-3662.
12. Zhang L, Smyrk TC, Young WF, et al. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol. 2010;34:53-64.
13. Miettinen M, Fetsch JF, Sobin LH, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006;30:90-96.
14. Kim SY, Wan X, Helman LJ. Targeting IGF-1R in the treatment of sarcomas: past, present and future. Bull Cancer. 2009;96:E52-E60.
15. Kolb EA, Gorlick R. Development of IGF-1R inhibitors in pediatric sarcomas. Curr Oncol Rep. 2009;11:307-313.
16. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol. 2010;28: 4985-4995.
17. Rosenzweig SA, Atreya HS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. 2010;80:1115-1124.
18. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol. 2008;20:419-427.
19. Agaram NP, Laquaglia MP, Ustun B, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008;14:3204-3215.
20. Braconi C, Bracci R, Bearzi I, et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol. 2008;19:1293-1298.
21. Janeway KA, Zhu MJ, Barretina J, et al. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer. 2010;127:2718-2722.
22. Pantaleo MA, Astolfi A, Di Battista M, et al. Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer. 2009;125:2991-2994.
23. Rios-Moreno MJ, Jaramillo S, Diaz-Delgado M, et al. Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res. 2011;31:3019-3025.
24. Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA. 2008;105:8387-8392.
25. Dziadziuszko R, Merrick DT, Witta SE, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol. 2010;28:2174-2180.
26. Golan T, Javie M. Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology. 2011;25:518-526.
27. Gridelli C, Rossi A, Bareschino MA, et al. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs. 2010;19:631-639.
28. Ozkan EE. Plasma and tissue insulin-like growth factor-1 receptor IGF-1R) as a prognostic marker for prostate cancer and anti-IGF-1R agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol. 2011;344:1-24.
29. Le Tourneau C, Siu LL. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol. 2008;20:256-263.
30. Scotlandi K, Manara MC, Nicoletti G. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005;65:3868-3876.